320406-05-1

Basic information

• Product Name: TERT-BUTYL 4-(4-CYANO-2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(4-CYANO-2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE;1-PIPERIDINECARBOXYLIC ACID, 4-[(4-CYANO-2-NITROPHENYL)AMINO]-, 1,1-DIMETHYLETHYL ESTER
• CAS NO: 320406-05-1
• Molecular Formula: C₁₇H₂₂N₄O₄
• Molecular Weight: 346.38098
• Mol File: 320406-05-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 500.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• PKA: -2.04±0.40(Predicted)
• CAS DataBase Reference: TERT-BUTYL 4-(4-CYANO-2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(4-CYANO-2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE(320406-05-1)
• EPA Substance Registry System: TERT-BUTYL 4-(4-CYANO-2-NITROPHENYLAMINO)PIPERIDINE-1-CARBOXYLATE(320406-05-1)

Safety Data

• Hazardous Substances Data: 320406-05-1(Hazardous Substances Data)

Upstream product

• 1009-35-4 4-fluoro-3-nitrobenzonitrile 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 

Downstream Products

• 1037834-87-9 1-{1-[2-(4-chlorophenyl)-2-oxoethyl]piperidin-4-yl}-5-(1H-tetrazol-5-yl)-1,3-dihydro-2H-benzimidazol-2-one 
• 1037834-88-0 1-{1-[2-(4-chlorophenyl)-2-hydroxyethyl]piperidin-4-yl}-5-(1H-tetrazol-5-yl)-1,3-dihydro-2H-benzimidazol-2-one 
• 1037834-92-6 1-{1-[2-(4-chlorophenyl)-2-oxoethyl]piperidin-4-yl}-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-benzimidazol-2-one 
• 1037834-93-7 1-{1-[2-(4-chlorophenyl)-2-hydroxyethyl]piperidin-4-yl}-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,3-dihydro-2H-benzimidazol-2-one 

Relevant articles and documents

SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY

There is provided herein a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3 and n have meanings provi

INHIBITORS OF SERINE PALMITOYLTRANSFERASE

This invention provides compounds of the formula (I) useful in the inhibition or modulation of serine palmitoyl transferase and their use in methods of treatment or amelioration of type 2 diabetes, type 1 diabetes, insulin resistance, the effects of obesity, metabolic syndrome (sometimes referred to as Syndrome X), impaired glucose tolerance, Cushing's disease, cardiovascular disease, prothrombotic conditions, myocardial infarction, hypertension, congestive heart failure, cardiomyopathy, atherosclerosis, dyslipidemia, sepsis, liver damage, retinal degenerative disorders, cachexia, emphysema, hepatitis C infections, HIV infections and inflammatory disorders and useful in methods for raising HDL plasma levels in a mammal. The compounds of this invention can also be used to prevent damage or loss of pancreatic islet beta cells (such as in the case of pancreatic beta cell apoptosis, including those related to insulin-dependent diabetes mellitus).